Clinical isolates of Pantone-Valentine leucocidin- and gamma-haemolysin-producing Staphylococcus aureus: prevalence and association with clinical infections

The Journal of Hospital Infection
I MesratiS Ben Redjeb

Abstract

Pantone-Valentine leucocidin (PVL) and gAMMA-haemolysin (Hlg) are members of the synergohymenotropic toxin family produced by Staphylococcus aureus and encoded by pvl and hlg genes, respectively. Many reports describe an association between PVL toxin and necrotic lesions involving skin and mucosa. The aim of this study was to determine the prevalence of S. aureus strains carrying pvl and hlg genes and to investigate a possible relationship between pvl- and hlg-positive S. aureus with specific clinical presentations. Between January 2005 and July 2007, a total of 143 S. aureus strains including 58 meticillin-resistant S. aureus (MRSA) and 85 meticillin-susceptible S. aureus were screened for pvl and hlg genes by multiplex polymerase chain reaction. These strains were isolated from 141 patients for whom demographic and clinical data were recorded. Thirty-one (21.7%) and 77 (53.7%) isolates were positive for pvl and hlg genes, respectively. Twenty-one (67.7%) pvl-positive strains were MRSA (P = 0.001). Among pvl-positive strains, 16 (51.6%) were community-acquired. There was a strong association between pvl genes and skin and soft tissue infections, especially abscesses (60% of strains; P = 0.008) and furunculosis (55.5% of strain...Continue Reading

References

Oct 1, 1991·Journal of Clinical Microbiology·K MurakamiS Watanabe
Apr 1, 1995·Journal of Medical Microbiology·G PrevostY Piemont
May 23, 1998·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G L Archer
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Dec 10, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·E J GorakJ D Brown
Apr 11, 2001·Emerging Infectious Diseases·B Shopsin, B N Kreiswirth
Jun 28, 2001·Japanese Journal of Infectious Diseases·T FujinoT Kirikae
Aug 31, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·T S NaimiK E Smith
Sep 14, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Philippe DufourHervé Richet
Feb 18, 2003·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C KesahM Borg
Dec 23, 2004·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John S FrancisJohn G Bartlett
Jun 30, 2005·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·O NolteH K Geiss
Feb 28, 2006·Diagnostic Microbiology and Infectious Disease·Mouna Ben NejmaMohamed Nour

❮ Previous
Next ❯

Citations

Dec 12, 2013·Der Hautarzt; Zeitschrift für Dermatologie, Venerologie, und verwandte Gebiete·C HammerJ Dissemond
Feb 1, 2013·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Samia HammamiIlhem Boutiba-Ben Boubaker
Aug 8, 2013·PloS One·Matthew E FalagasIoanna P Korbila
Dec 21, 2012·Future Microbiology·Mathias HerrmannMartin P Grobusch
Feb 6, 2013·Infection and Immunity·Ranjani PrabhakaraTod J Merkel
Mar 27, 2012·Journal of Bacteriology·Mark A SchallenbergerFloyd E Romesberg
May 29, 2015·Clinical Microbiology Reviews·Steven Y C TongVance G Fowler

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.